medigraphic.com
ISSN 0210-5187 (Electronic)

2019, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2019; 47 (1)

Acne news

Medina CDE, Aguilar MDA, Freyat AA, Piquero MJ, Poletti VED

Language: Spanish
References: 34
Page: 7-15
PDF size: 326.77 Kb.


ABSTRACT

Acne is an inflammatory disease of the pilosebaceous complex. It is one of the most frequent diseases worldwide and affects mainly the adolescent population. There are news in terms of physiopathology, phylogenetics that has shown other genes within the filum propinebacteriaceas and that have given rise to the new name of Propionibacterium acnes to Cutibacterium acnes. The therapeutic modalities are broken down, among which there are topical and oral medications with different mechanisms of action including biological and target molecules to combat sebum-regulation, anti-inflammatory and anti-androgens. The study of the microbiome and intestinal dysbiosis that produces alterations in the skin and the resurgence of probiotics. The myths have been diluted in terms of the existing relationship of acne with diet and have even been based on the prevention of cardiovascular diseases.


REFERENCES

  1. Rathi SK. Acne and treatment: the current scenario. Indian J Dermatol. 2011; 56: 7-13.

  2. Friendlander SF, Eichenfield LF, Fowler JF Jr, Fried RG, Levy ML, Webster GF. Acne epidemiology and pathophysiology. Sem Cutan Med Surg. 2010; 29 (2 Suppl 1): 2-4.

  3. Dréno B. Treatment of adult female acne: a new challenge. JEADV. 2015; 29 Suppl 5: 14-19.

  4. Poletti-Vázquez ED, Hernández-Collazo AA. Acné: nuevas tendencias, mejores estrategias. En: Sociedad Mexicana de Dermatología A.C.; Arenas-Guzmán R, Torres-Guerrero E, Salazar-Rojas E, coordinadores. PRODERMA Programa de Actualización en Dermatología: Ciclo 1. Ciudad de México: Artmed Panamericana; 2017. pp. 73-108 (Sistema de Educación Continua a Distancia, v. 1).

  5. Arostegui JI. Enfermedades autoinflamatorias sistémicas hereditarias. Reumatol Clin. 2011; 7: 45-50.

  6. Maldonado GCA, Lin S. Articulo de revisión: foliculitis infecciosas (parte I). Rev Cent Dermatol Pascua. 2014; 23: 90-98.

  7. Chirino ME, Villa R, Florencia RM, Pedrozo L, Rodríguez SS. Enfermedad de Morbihan: exitosos tratamiento con isotretinoina oral. Arch Arg Dermatol. 2016; 66: 5-8.

  8. Morales TA, Ocampo CJ. Acné panorama general y terapéutica actual. Dermatogia CMQ. 2009; 7: 18-25.

  9. Dréno B, Precastaing S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018; 32 Suppl 2: 5-14.

  10. O’Neil AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome. 2018; 6: 177-193.

  11. Grupo Colombiano para el Estudio del Acné; Orozco B, Velásquez MM, Meléndez E, Pabón JG, Motta A, Anaya L et al. Vías inflamatorias en la fisiopatología del acné. Rev Asoc Colomb Dermatol. 2013; 21: 339-359.

  12. Guerra TA, de Lucas LR, Moreno GJC, Pérez LM, Rivera PM, Martínez PE et al. Consenso en el tratamiento tópico del acné. Med Cutan Iber Lat Am. 2015; 43: 104-121.

  13. Fierro-Arias L, Lopez-Gehrke I. Nadifloxacino. Dermatol Rev Mex. 2016; 60: 37-44.

  14. Work Group: Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 945-973e33

  15. Clavellina MM, Moreno CG. Dapsona su uso en dermatología. Dermatología CMQ. 2014; 12: 47-51.

  16. Bettoli V, Zauli S, Borghi A, Toni G, Ricci M, Bertoldi AM et al. Efficacy and safety of a 12 month treatment with a combination of hidroxipinacolona retinoate and retinol glycospheres as maintenance therapy patients after oral isotretinoin. G Ital Dermatovenereol. 2017; 152: 13-17.

  17. Truchuelo MT, Jimenez N, Mavura D, Jaén P. Assessment of the efficacy and safety of a combination of topical retinoids (retinsphere) in maintaining post treatment response of acne to oral isotretinoin. Actas Derm Sifilogr. 2015; 106: 126-132.

  18. Trivedi MK, Bosanac SS, Sivamani RK, Larsen LN. Emerging therapies for ace vulgaris. Am J Clin Dermatol. 2018; 19: 505-516.

  19. Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona-Cabal MI et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018; 78 (2S1): S1-S23.e1.

  20. Fabbrocini G, Panariello L, Donnarumma M, Mazzella C. Effectiveness and tolerability of a topical gel containing hydrogen peroxide, salicylic acid and d-panthenol in the treatment of mild-moderate acne. Eur J Acne Rel Dis. 2014; 5: 69-71.

  21. Ricci F, Masini F, Fossati B, Frascione P, De Waure C, Capizzi R et al. Combination therapy with hydrogen peroxide (4%), salicylic acid (0.5%) and D-panthenol (4%): efficacy and skyn tolerability in common acne vulgaris during sun exposure period. Eur Rev Med Pharmacol Sci. 2016; 20: 232-236.

  22. Dréno B, Nocera T, Verrière F, Vienne MP, Ségard C, Vitse S et al. Topical retinaldehyde with glycolic acid: study of tolerance and acceptability in association with anti-acne treatments in 1,709 patients. Dermatology. 2005; 210 (Suppl 1): 22-29.

  23. Zouboulis CC, Dessinioti C, Tsatsou F, Gollnick HPM. Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2017; 26: 813-823.

  24. Feuillolay C, Pecastaings S, Le Gac C, Fiorini-Puybaret C, Luc J, Joulia P et al. A Myrtus communis extract enriched in myrtucummulones and ursolic acid reduces resistance of Propionibacterium acnes biofilms to antibiotics used in acne vulgaris. Phytomedicine. 2016; 15: 307-315.

  25. Guzman AK, Choi JK, James WD. Safety and effectiveness of amoxicillin in the treatment of inflammatory acne. Int J Womens Dermatol. 2018; 4: 174-175.

  26. Cervantes J et al. The role of zinc in the treatment of acne: a review of the Literature. Dermatologic Therapy. 2017; e125-e176.

  27. Gupta VK, Mahajan KSM, Pushpinder SC. Zinc therapy in dermatology: a review. Dermatol Res Pract. 2014; 2014: 1-11.

  28. Guy F, Webster MD et al. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-lidose) and the innovator isotretinoin formulation: A randomized, 4-treatment, crossover study. J Am Acad Dermatol. 2013; 69: 762-767.

  29. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbioma as a major regulator of the gut-skin axis front. Microbiol. 2018; 9: 1459.

  30. Vulgaris I, Brahim AA, Salem RM, El-Shimi OS, Baghdady SMA, Hussein S. IL1A (-889) gene polymorphism is associated with the effect of diet as a risk factor in acne. J Cosmet Dermatol. 2018; 1. doi: 10.1111/jocd.12516. [Epub ahead of print].

  31. Melnik BC. Acne vulgaris: the metabolic syndrome of the pilosebaceous follicle. Clin Dermatol. 2018; 36: 29-40.

  32. Maarouf M, Platto JF, Shi VY. The role of nutrition in inflammatory pilosebaceous disorders: implication of the skin?Gut axis. J Austral Dermatol. 2018. Disponible en: https://doi.org/10.1111/ajd.12909.

  33. Stewart TJ, Bazergy C. Hormonal and dietary factors i acné vulgaris versus controls. Demato-Endocrinol . 2018; 10: 1-4.

  34. Dai R, Hua W, Chen W, Xiong L. The effect of milk consumption on acné a metaanalisis of observational studies. J Eur Acad Dermatol Venereol. 2018; 32: 2244-2253.




2020     |     www.medigraphic.com